Date:6/19/2008

is press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include statements about future sales of Zevalin and the development of OPAXIO and pixantrone which include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with OPAXIO and pixantrone in particular, including, without limitation, the potential failure of these product candidates to prove safe and effective for treatment of non-small cell lung cancer, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma, determinations by regulatory, patent and administrative governmental authorities including but not limited to decisions regarding the review and approval of applications submitted to the FDA or the EMEA, competitive factors, technological developments, costs of developing, producing and selling Zevalin, OPAXIO and pixantrone, the outcome of clinical trial results for ongoing trials of our drugs, including pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Cell Therapeutics, Inc.

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Lindsey Jesch

T : 206.272.4347

F : 206.272.4434

E: media@ctiseattle.com

http://www.CellTherapeutics.com/media.htm

Investors Contact:

Cell Therapeutics, Inc.

Ed Bell

T: 206.272.4345

<
'/>"/>

SOURCE Cell Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
4. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
5. Pharmos Issues Letter to Shareholders
6. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
7. YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF SHAREHOLDERS AND NOMINATION OF DIRECTORS
8. YM Biosciences announces adoption of renewed Shareholders Rights Plan
9. Isolagen, Inc. Reports Results of Shareholders Annual Meeting
10. CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders